Physician profile
Ali Bagheri
NPI 1265469522
$11,453.76
in general payments reported to CMS, 2019-2025
31 companies · $3,363 in 2025
The $3,363 reported for 2025 was more than what 98% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,209 · 2020: $630 · 2021: $1,160 · 2022: $1,278 · 2023: $1,351 · 2024: $1,463 · 2025: $3,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,165 · Travel and Lodging: $13.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,164.50 |
| Travel and Lodging | $13.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $2,369.68 | 2025 | Rapiblyk |
| Janssen Pharmaceuticals, INC | $1,842.16 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $762.84 | 2019-2023 | Lokelma |
| Ferring Pharmaceuticals INC. | $744.42 | 2023-2025 | Rebyota |
| Pfizer INC. | $609.17 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.90 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $563.48 | 2022-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $502.21 | 2019-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $493.92 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $454.56 | 2019-2021 | |
| Shionogi INC | $406.25 | 2022-2025 | Fetroja |
| Novartis Pharmaceuticals Corporation | $268.29 | 2019-2020 | |
| Csl Behring | $268.02 | 2019-2025 | Kcentra |
| Vifor Pharma, INC. | $202.24 | 2019-2023 | Veltassa |
| Gilead Sciences, INC. | $201.94 | 2021-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $149.99 | 2025 | Vowst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $146.29 | 2025 | Lifevest |
| Abbvie INC. | $142.41 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $132.76 | 2022-2025 | Ultomiris |
| Biogen, INC. | $123.04 | 2019 | |
| Orthofix Medical, INC. | $107.78 | 2019 | |
| Paratek Pharmaceuticals, INC. | $94.68 | 2019-2024 | Nuzyra |
| Titan Spine, LLC | $57.48 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $54.52 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $49.82 | 2025 | |
| Novo Nordisk INC | $22.47 | 2019 | |
| Ardelyx, INC. | $20.05 | 2022 | |
| Melinta Therapeutics, LLC | $17.01 | 2025 | Rezzayo |
| Mylan Specialty L.P. | $16.71 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.89 | 2019 | |
| Seaspine Orthopedics Corporation | $13.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Bagheri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.